BAR­DA awards Emer­gent 10-year, $704M con­tract for Ebo­la treat­ment

Emer­gent BioSo­lu­tions has land­ed a $704 mil­lion con­tract from BAR­DA.

The man­u­fac­tur­er an­nounced the BAR­DA award on Tues­day for a 10-year con­tract to de­vel­op and scale up the pro­duc­tion of the Ebo­la treat­ment Eban­ga. Emer­gent will scale up the man­u­fac­tur­ing of Eban­ga which in­cludes tech trans­fers, sub­mis­sion of a sup­ple­men­tal BLA to the FDA and sta­bil­i­ty stud­ies. Eban­ga was ap­proved by the FDA to treat Ebo­la in 2020.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER